Orbital Tumours: An Overview

Jawad Ahmad

Learning Points

  • Orbital tumours are rare but potentially sight- and life-threatening (1, 2).
  • The orbit hosts many benign and malignant entities with characteristic clinical–imaging patterns (3, 4).
  • Proptosis is common; the tempo (rapid vs slow) and tenderness help narrow the differential (5).
  • MRI and CT are complementary for localisation, characterisation, and surgical planning (6).
  • Early multidisciplinary referral improves visual and oncologic outcomes (7, 8).

Summary

Orbital tumours comprise a heterogeneous group of benign and malignant lesions that may be primary, secondary, or metastatic. Because of the orbit’s compact anatomy, small masses can cause proptosis, diplopia, or visual loss (2, 5). This educational overview summarises classification, presentation, investigation, and management for students and junior clinicians. Maintaining a high index of suspicion and referring early to an ophthalmic oncology or oculoplastic centre helps preserve vision and, in malignant disease, can be lifesaving (7).

Introduction

The orbit is a pyramidal space containing the globe, extraocular muscles, optic nerve, vessels, fat, and connective tissue (1). Space-occupying lesions disturb this balance and may present with unilateral progressive proptosis, diplopia, or decreased vision; acute painful swelling suggests inflammation, infection, or a rapidly enlarging tumour (5).

Epidemiology

Orbital tumours are uncommon, representing approximately 0.1 % of all neoplasms (2). In children, benign lesions such as dermoid cysts and vascular malformations predominate, whereas in adults, malignant processes including lymphoma, metastases, and lacrimal-gland tumours are more common (3). There is no clear overall sex bias, although meningioma shows a female predominance (4). Modern imaging has increased incidental detection (6).

Anatomy and Pathophysiology

Lesions may arise from the intraconal or extraconal compartments. They can be:

  • Primary (e.g. cavernous venous malformation, optic nerve glioma) (5),
  • Secondary (extension from paranasal sinuses or eyelids), or
  • Metastatic (spread from breast, lung, or prostate carcinoma) (5).

Classification

Tissue of originExample lesions
VascularCavernous venous malformation, lymphatic malformation, solitary fibrous tumour
NeuralOptic nerve glioma, meningioma, schwannoma
Lacrimal glandPleomorphic adenoma (benign), adenoid cystic carcinoma (ACC; malignant)
LymphoidOcular adnexal lymphoma
MesenchymalRhabdomyosarcoma
Secondary / MetastaticBreast, lung, prostate, kidney

Rhabdomyosarcoma predominates in children, while lymphoma and metastatic carcinoma are most common in adults (6).

Presentation

Slow, painless proptosis usually indicates a benign lesion such as cavernous venous malformation (2). Rapid, painful proptosis suggests infection, inflammation, or malignancy (5). Other signs include diplopia, optic-nerve compression, lid swelling, lacrimal-fossa mass, or pain from perineural invasion (12).

Differential Diagnosis

Thyroid eye disease, idiopathic orbital inflammation, cellulitis, and vascular malformations can mimic tumours. Inflammatory lesions are typically painful with acute onset and steroid responsiveness, whereas neoplastic lesions progress gradually and painlessly (5).

Investigations

Imaging: CT delineates bone erosion and calcification; MRI gives superior soft-tissue contrast and optic-nerve detail (6).
Biopsy: Histopathological confirmation is required for most lesions. Fine-needle aspiration biopsy (FNAB) may be used for accessible lesions but should be avoided in suspected pleomorphic adenoma due to seeding risk (8, 9).
Systemic work-up: Blood tests and systemic imaging help detect metastasis or systemic lymphoma (11).

Referral and Multidisciplinary Approach

All suspected orbital tumours should be referred urgently to an ophthalmic oncology or oculoplastic centre. An MDT—typically including ophthalmologist, radiologist, pathologist, oncologist, and radiotherapist—optimises staging and management (7, 11).

Management

Benign tumours: Observation is acceptable if asymptomatic. Surgical excision is indicated when vision or cosmesis is threatened. Modern orbitotomy and endoscopic endonasal approaches reduce morbidity (10, 13).

Malignant tumours:

  • Lymphoma (OAL): Managed primarily with radiotherapy; chemotherapy added for advanced disease (11, 14).
  • Lacrimal gland ACC: Pain and perineural spread are characteristic. Eye-sparing resection plus adjuvant radiotherapy achieves outcomes comparable to cranio-orbital resection (12, 15).
  • Rhabdomyosarcoma: Treated with combined chemo- and radiotherapy (6).
  • Metastases: Managed palliatively, often with radiotherapy or targeted systemic therapy (5).

Complications and Follow-up

Untreated orbital tumours can cause optic atrophy, diplopia, cosmetic deformity, or intracranial extension. Post-operative complications include infection, scarring, and vision loss. Long-term follow-up is critical, especially for ACC (late recurrence) and lymphoma (contralateral or systemic relapse) (12, 14, 15).

Prognosis

Benign lesions such as cavernous venous malformation have excellent outcomes after excision (10). Localised OAL achieves >90 % 5-year survival (14). Lacrimal-gland ACC has ~60 % 5-year survival with risk of late recurrence (12, 15).

Recent Advances

Diffusion-weighted MRI and navigation-guided minimally invasive surgery enhance safety and diagnosis. Targeted immunotherapy and stereotactic radiotherapy continue to expand treatment options (16).

References

  1. Rootman J. Diseases of the Orbit: A Multidisciplinary Approach. Philadelphia: Lippincott Williams & Wilkins; 2003.
  2. Bonavolontà G, Tranfa F, Vassallo P, Strianese D. An analysis of 2,480 space-occupying lesions of the orbit. Ophthalmic Plast Reconstr Surg. 2013;29(2):79–86. PMID: 23470516.
  3. Shields JA, Shields CL. Orbital Tumors. Philadelphia: Lippincott Williams & Wilkins; 2007.
  4. Saeed P, van Furth WR, Tanck M, et al. Clinical characteristics and treatment outcomes of orbital meningiomas. Br J Ophthalmol. 2011;95(7):996–1000. PMID: 21242579.
  5. Dutton JJ. Clinical features of orbital tumors. Surv Ophthalmol. 1994;38(4):385–408. PMID: 8003823.
  6. Tailor TD, Gupta D, Dalley RW, Keene CD, Anzai Y. Orbital neoplasms in adults: clinical, radiologic and pathologic review. Radiographics. 2013;33(6):1739–1758. PMID: 24108560.
  7. Rose GE, Wright JE. Pleomorphic adenoma of the lacrimal gland. Br J Ophthalmol. 1992;76(7):395–400. PMID: 1320923.
  8. Mombaerts I. Diagnostic principles in orbital disease: biopsy first. Acta Ophthalmol. 2016;94(5):478–483. PMID: 26994870.
  9. Kennerdell JS, Slamovits TL, Dekker A. Orbital fine-needle aspiration biopsy. Arch Ophthalmol. 1985;103(12):1869–1873. PMID: 4003490.
  10. Sindwani R, et al. Endoscopic endonasal approach to intraconal orbital tumors: indications, technique, and outcomes. Laryngoscope. 2024;134:47–55. PMID: 37249188.
  11. Yen MT, Bilyk JR, Bradley EA, et al. Treatments for ocular adnexal lymphoma: AAO preferred practice pattern. Ophthalmology. 2018;125(1):127–136. PMID: 28712656.
  12. Esmaeli B, Ahmadi MA, Youssef A, et al. Adenoid cystic carcinoma of the lacrimal gland: results of combined surgery and radiation. Ophthalmology. 2004;111(5):963–970. PMID: 14752305.
  13. Mueller SK, Bleier BS. Endoscopic surgery for intraconal orbital tumors. HNO. 2022;70(5):345–351. PMID: 35298667.
  14. Martinet S, Ozsahin M, Belkacémi Y, et al. Outcome and prognostic factors in orbital lymphoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2003;55(4):892–898. PMID: 12605966.
  15. Rose GE, Gore S, Plowman PN, et al. Eye-sparing surgery with adjuvant radiotherapy versus cranio-orbital resection for lacrimal gland carcinoma. Ophthalmology. 2019;126(12):1727–1735. PMID: 30130333.
  16. Ioakeim-Ioannidou M, Sayan M, Damato B, et al. Radiotherapy for orbital tumors: evolution of indications and techniques. Semin Radiat Oncol. 2020;30(4):318–332. PMID: 33072488.
Tags: , , , , ,

Leave a Reply